Long-Acting Injectable Antipsychotics: Clinical Positioning and Recommendations

Introduction to LAI Antipsychotics

Second-generation LAIs are preferred due to better tolerability and fewer neurological side effects, as recommended by the British Journal of Psychiatry 1

Second-generation LAIs are recommended as first-line maintenance treatment after the first episode of schizophrenia, representing a shift from historical practice patterns that reserved LAIs for patients with documented non-adherence or frequent relapses 1
The British Journal of Psychiatry recommends LAIs for relapse prevention, as they are superior to oral medications in preventing relapse due to guaranteed medication delivery 1
LAIs reduce hospitalization rates as a consequence of improved adherence, according to the British Journal of Psychiatry 1
The expert consensus, as reported in the British Journal of Psychiatry, recommends systematically offering LAI antipsychotics to most patients requiring long-term antipsychotic treatment through shared decision-making, and not reserving them only for patients who have already experienced multiple relapses or demonstrated poor adherence 1
Studies demonstrate that 83-85% of eligible first-episode patients consent to LAI treatment when properly educated, as reported in the British Journal of Psychiatry 2
Only 15% of first-episode patients refused LAI treatment in one study of 60 patients, according to the British Journal of Psychiatry 2

The combination of long-acting injectables with oral medications has been associated with reduced psychiatric hospitalization risk (7-13% lower) and represents some of the most effective treatment strategies in large-scale observational studies, according to the British Journal of Psychiatry 3, 4

Any patient requiring long-term antipsychotic treatment should be considered a candidate for LAI formulations, not just those with documented non-adherence, as suggested by the British Journal of Psychiatry 5
Patients with irregular medication-taking patterns, given the established relationship between non-adherence and relapse risk, should be considered for LAI treatment, according to the British Journal of Psychiatry 5
Patients experiencing recurrent relapses despite oral antipsychotic trials should be considered for LAI treatment, as recommended by the British Journal of Psychiatry 5

Treatment should start as soon as possible after improvement of acute symptoms, once dosage flexibility is no longer required, as suggested by the British Journal of Psychiatry 5
Assessing treatment indication and evaluating oral olanzapine response are crucial steps in the clinical implementation algorithm for OLAI, with the British Journal of Psychiatry recommending a systematic approach to offering LAIs to patients requiring long-term antipsychotic therapy 5

Long-acting injectable olanzapine pamoate is available and represents the most direct transition option for patients already stabilized on oral olanzapine, as it maintains the same pharmacological profile the patient has already demonstrated tolerability to 6

Gradual cross-titration should be performed when switching between different antipsychotic agents, informed by the half-life and receptor profile of each medication 7
For patients switching from olanzapine to risperidone or paliperidone, consider that these are D2 antagonists rather than the broader receptor profile of olanzapine 7
Metformin should be offered concomitantly if metabolic concerns arise with any antipsychotic choice 7

Patients who demonstrate irregular medication‑taking patterns should be offered long‑acting injectable (LAI) antipsychotics because non‑adherence is strongly linked to increased relapse risk in schizophrenia. 8

After acute psychotic symptoms have improved and dosage flexibility is no longer needed, clinicians should initiate LAI therapy as early as possible to maintain stabilization. 8
During the acute phase, oral antipsychotics or short‑acting intramuscular injections are preferred to allow dose adjustments; LAIs are introduced only after the patient is clinically stable. 8

The primary criterion for choosing an LAI is the patient’s prior response and tolerability to a specific oral antipsychotic; the corresponding LAI formulation should be selected when available. 8
When multiple LAIs are appropriate, selection should incorporate the patient’s expressed preference and the pharmacokinetic characteristics of each formulation (e.g., dosing interval, steady‑state time). 8
Current evidence does not demonstrate superiority of any single LAI regarding efficacy, although side‑effect profiles differ among agents. 8

Clinicians should not view an initial refusal of LAI therapy as permanent; ongoing therapeutic dialogue can help patients understand the potential benefits and may lead to later acceptance. 8
Treatment resistance should not be diagnosed without first assessing adherence; pseudo‑resistance due to missed doses is common, and drug plasma levels are rarely measured before labeling a patient as resistant. 9